spacer
home > epc > winter 2003 > why conduct clinical trials in central and eastern europe?
PUBLICATIONS
European Pharmaceutical Contractor

Why Conduct Clinical Trials in Central and Eastern Europe?

How Toxic are Clinical Delays for the Industry?

With 80 per cent of clinical trials suffering delays of two to six months, entire programmes are being set back by one to four years. Delays in clinical R&D tend to cumulate from study to study, and those relating to studies on the critical path, by definition, have a negative impact on the whole development programme. Suppose there are six, 12 or 18 studies on the critical path of three different programmes and the average time lost per study is two months - the bare minimum.

The corresponding programmes will be delayed by 12, 24 and 36 months, respectively. At an opportunity cost of no less than US$500 million per year, clinical delays become lethally toxic to the pharmaceutical industry. To make matters worse, as the programme progresses, studies, which were not on the critical path in the original plan, may now become time-critical because of cumulative delays upstream.

Delays tend to cascade in clinical programmes. It is likely that the causes which hindered earlier studies, such as lack of patients, will persist from study to study. It is very difficult to ask teams downstream to compensate for the delays of teams upstream in the process. It is even tough to blame a team for delays in any single project because responsibilities are diffuse, and individuals will reject blame when responsibilities are collective. In addition, fear of blame is not a stimulating R&D environment. As a result, no-fault responsibility becomes the rule.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Jean-Pierre Tassignon, Executive Vice-President at PSI Pharma Support Intl

Dr Jean-Pierre Tassingnon is Executive Vice-President of PSI Pharma Support International AG in Switzerland, a position he has held for eight years. He is trained in Medicine and Business Administration, and has diplomas in Pharmaceutical and Industrial Medicine. Jean-Pierre began his career as a Corporate Counsellor for Industrial Medicine and Toxicology at Solvay in 1974, where he stayed for 14 years. In 1982 he became International Medical Director at Solvay and then joined Covance in 1988 as Executive Vice President in Europe for Corning-Besselaar, where he remained until 1992. Jean-Pierre is on the Board of Examiners and lectures post graduates in pharmaceutical medicine at Universitй Libre de Bruxelles.

spacer
Dr Jean-Pierre Tassingnon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Stripping the confusion out of PVC curtains... and a new seat range.

Teknomek Ltd

With the ever-growing trend towards modularisation of clean rooms and laboratories; Teknomek have responded with a new range of PVC strip curtains, suitable for use in environments where maintaining clean airflow is critical. This new PVC curtain range includes specialist perforated and electrostatic discharge alternatives to the standard options of clear and polar (-25oC) versions.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement